Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 6.68B +117.5% |
| Revenue (ttm) | 3.12B +9.3% |
| Net Income | 157.36M +4,562.6% |
| EPS | 0.48 +4,332.0% |
| Shares Out | 348.30M |
| PE Ratio | 39.89 |
| Forward PE | 19.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,286,719 |
| Open | 19.28 |
| Previous Close | 19.25 |
| Day's Range | 18.94 - 19.39 |
| 52-Week Range | 9.75 - 21.18 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 22.71 (+18.41%) |
| Earnings Date | Nov 3, 2026 |
About AMRX
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and res... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for AMRX stock is "Strong Buy." The 12-month stock price target is $22.71, which is an increase of 18.41% from the latest price.
News
Amneal to Report Third Quarter 2026 Results on November 3, 2026
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tue...
Amneal Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Amneal Pharmaceuticals (AMRX) with an Outperform rating and $27 price target The firm believes Amneal is at a “fundamental inflection.” The company’s “differentiated”...
Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide
Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product refer...
Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal Pharmaceuticals price target raised to $20 from $16 at Barclays
Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $20 from $16 and keeps an Overweight rating on the shares. The pending gLanreotide approval, which is expected any…
Leerink bullish on Amneal Pharmaceuticals, initiates with an Outperform
As previously reported, Leerink initiated coverage of Amneal Pharmaceuticals (AMRX) with an Outperform rating. The firm names the stock a Top Pick, citing Affordable Medicines momentum, biosimilars up...
Amneal Pharmaceuticals initiated with an Outperform at Leerink
Leerink initiated coverage of Amneal Pharmaceuticals (AMRX) with an Outperform rating and $23 price target
Amneal Pharmaceuticals resumed with an Overweight at JPMorgan
JPMorgan resumed coverage of Amneal Pharmaceuticals (AMRX) with an Overweight rating and price target of $22, up from $18, following a period of restriction. The firm views the company as…
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWA...
Amneal Pharmaceuticals price target raised to $25 from $23 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $25 from $23 and keeps a Buy rating on the shares. Amneal’s strong Q2 beat and…
Amneal Pharmaceuticals price target raised to $25 from $23 at UBS
UBS raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $25 from $23 and keeps a Buy rating on the shares.
Amneal Pharmaceuticals price target raised to $25 from $23 at UBS
UBS raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $25 from $23 and keeps a Buy rating on the shares. Amneal’s strong Q2 beat and raised outlook create…
Amneal Pharmaceuticals Transcript: EGM 2026
Stockholders approved the acquisition of Kashiv BioSciences, LLC and the issuance of new shares to sellers, with both proposals receiving unanimous board support and no questions from stakeholders. Official results will be announced after verification.
Amneal Pharmaceuticals price target raised to $21 from $19 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $21 from $19 and keeps a Buy rating on the shares.
Amneal Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw double-digit revenue and profit growth, driven by strong performance in affordable medicines, specialty, and biosimilars. The company raised its full-year outlook and is set to close the Kashiv acquisition, expanding its biosimilar platform and pipeline.
Amneal Pharmaceuticals Earnings release: Q2 2026
Amneal Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Amneal Pharmaceuticals Slides: Q2 2026
Amneal Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Amneal Pharmaceuticals Quarterly report: Q2 2026
Amneal Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on July 30, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals reports Q2 adjusted EPS 30c, consensus 23c
Reports Q2 revenue $796M, consensus $770.91M. “Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and t...
Amneal Pharmaceuticals raises 2026 adj EPS view to 96c-$1.06 from 95c-$1.05
2026 EPS consensus 98c. Raises 2026 revenue view to $3.10B-$3.20B from $3.05B-$3.15B, consensus $3.12B. Raises 2026 CapEx view to $150M from $110M.
Amneal Reports Second Quarter 2026 Financial Results
– Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million ; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Ye...
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders. The investigation seeks to determine...
Amneal receives FDA approval for additional iohexol strengths, presentations
Amneal Pharmaceuticals (AMRX) announced that it has received FDA approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 100 mL…
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that it has received U.S. Food and Drug Administration (FD...